We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Entering the first full trading hour of Wednesday's session, Madison Mills monitors several of the day's developing market ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Mark Groves is a human connection specialist who teaches individuals and companies how to strengthen their relationships.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...

Payer profits fell in 2024 as Americans, especially older ones, utilized more medical care. But efforts to resuscitate ...